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Interleukin-17A (IL-17A) is the signature cytokine produced by Th17 CD4þ T cells and has been tightly
linked to autoimmune pathogenesis. In particular, the transcription factors NFAT and RORgt are known to
activate Il17a transcription, although the detailed mechanism of action remains incompletely under-
stood. Here, we show that the nuclear orphan receptor NR2F6 can attenuate the capacity of NFAT to bind
to critical regions of the Il17a gene promoter. In addition, because NR2F6 binds to deﬁned hormone
response elements (HREs) within the Il17a locus, it interferes with the ability of RORgt to access the DNA.
Consistently, NFAT and RORgt binding within the Il17a locus were enhanced in Nr2f6-deﬁcient CD4þ Th17
cells but decreased in Nr2f6-overexpressing transgenic CD4þ Th17 cells. Taken together, our ﬁndings
uncover an example of antagonistic regulation of Il17a transcription through the direct reciprocal actions
of NR2F6 versus NFAT and RORgt.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
CD4þ Th17 cells are important for immune defense against
bacteria and fungi [1]. Moreover, this T cell subset produces the
proinﬂammatory effector cytokines interleukin (IL)-17A and IL-17F,
which are involved in tissue inﬂammation and contribute to
autoimmune disorders such as arthritis, multiple sclerosis, Crohn’s
disease, uveitis and psoriasis [1e4]. Therefore, recent research has
focused on a detailed mechanistic analysis of the transcriptional
regulation of the Il17a gene promoter [5e10]. Commitment to the
Th17 lineage is dependent on T cell receptor signaling and requires
IL-6- and TGFb-induced signaling cascades [11]. In addition, IL-1b
has been shown to be important and can substitute for TGFb during
early Th17 differentiation [12,13]. Several distinct components of
the TCR signaling cascade have been speciﬁcally linked to CD4þ
Th17 subset differentiation, such as the AP-1 transcription factor
family member B cell-activating transcription factor (Batf), the
Rel/NF-kB member c-Rel, Ikappaz (IkBz) and the Tec family tyrosine
kinase member inducible T cell kinase (Itk) [5,8,9,14]. Itk speciﬁ-
cally regulates NFATc1 binding to the Il17a promoter and activates0514/70517; fax: þ43 (0)512
at (N. Hermann-Kleiter),
-NC-ND license.the transcription of Il17a but not Il17f, Il17a appears to be the more
pathogenic cytokine involved in the autoimmune response [9].
Several conserved noncoding sites (CNS) have been identiﬁed
within the Il17aeIl17f locus, and the CNS2 region in particular has
been associatedwith the permissive hyperacetylation of histone H3
[1,13e15]. Recently, it has been shown that the CNS2 region is
necessary and sufﬁcient for Il17a transcription and optimal Il17f
gene transcription in Th17 cells [5].
CD4þ Th17 differentiation is initiated by the subset-speciﬁc
transcription factors retinoic acid-related orphan receptor (ROR)gt
and RORa in combination with other transcription factors, such as
the aryl hydrocarbon receptor (Ahr), the Runt-related transcription
factor 1 (Runx1), interferon regulatory factor 4 (IRF4) and the signal
transducer and activator of transcription 3 (STAT3). The coordinated
activity of these factors subsequently induces the transcription of
CD4þ Th17 cytokines including Il17a, Il17f, Il21, Il22, Il23 and Csf2r
[7,16e18].
The secretion of these proinﬂammatory cytokines by CD4þ Th17
cells must be tightly controlled to avoid tissue damage and auto-
immune responses. Several negative regulators of CD4þ Th17
differentiation and function have been identiﬁed, including the
transcription factors forkhead box protein P3 (Foxp3), signal
transducer and activator of transcription 5 (STAT5), suppressor of
cytokine signaling 3 (SOCS3), eomesodermin, growth factor-
independent 1 (Gﬁ1), v-ets erythroblastosis virus E26 oncogene
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DNA binding 3 (Id3) [16,19e26].
There is also emerging evidence for biologically important roles
of nuclear receptor signaling in the regulation of Th17 subset
differentiation and function [27]. Members of the nuclear receptor
family regulate the CD4þ Th17 T cell response with reciprocal
outcomes; the RAR-related orphan receptors (RORg/NR1F3 and
RORa/NR1F3-A) are key transcriptional activators, whereas retinoic
acid receptor (RAR/NR1B1), retinoid X receptor (RXR/NR2B1),
nuclear receptor subfamily 2 group F member 6 (Ear2/NR2F6),
peroxisome proliferator-activated receptor gamma (PPARg/
NR1C3), liver X receptor (LXR/NR1H), glucocorticoid receptor (GR/
NR3C1), the vitamin D receptor (VDR/NR1I1) and the estrogen
receptor (ER NR3A1) contribute anti-inﬂammatory effects
[16,18,28e30].
We have previously demonstrated that the nuclear orphan
receptor NR2F6 potently antagonizes the ability of Th17 CD4þ T
cells to induce the expression of Il17a in an NFAT-speciﬁc fashion
[18]. As the precise mode of Il17a transcriptional regulation via
NR2F6 has remained unclear, we investigated in detail how, where
and in what context NR2F6 attenuates the DNA accessibility of
NFAT and RORgt. We identiﬁed a crucial role for NR2F6 in the direct
binding to multiple sites within the locus encoding Il17a. The
subsequent suppression of Il17a transcription by NR2F6 represents
an important physiological mechanism controlling Th17 cell
effector functions.2. Material and methods
2.1. Mice
Nr2f6-deﬁcient mice [18] between the ages of 6e12 weeks were
used for the experiments. Nr2f6-Tg85 transgenic mice were gener-
ated by pronuclear injection (C57Bl/6mouse eggs) of linearized and
puriﬁed CAG-mNr2f6-2A-EGFP DNA. Transgenic mice were
selected by PCR analysis of tail DNA with TaqMan probes for EGFP
(probes from ABI) and were maintained on the C57/Bl6 back-
ground. The experimental protocols and animal care and handling
methods conformed to the Swiss federal law for animal protection.
The studies described in this report were performed according to
the Novartis animal license numbers 1022 and 1331. B6.129P2(Cg)-
Rorctm2Litt/J mice of 8e12 weeks of age were obtained from the
Jackson laboratory. OTII mice obtained from Charles River Labora-
tories were crossed onto the Nr2f6-deﬁcient C757Bl6 background.
The mice were maintained under speciﬁc pathogen-free (SPF)
conditions, and all animal experiments were performed in accor-
dance with the Austria “Tierversuchsgesetz” (BGBI. Nr. 501/1988
i.d.g.F.) and have been granted by the Bundesministerium für Bil-
dung, Wissenschaft und Kultur (bm:bwk).2.2. MOG35e55-induced EAE
Female mice were injected subcutaneously at the tail base with
200 mg MOG35e55 peptide (100 ml) (PolyPeptide group, France) in
complete Freund’s adjuvant (CFA) containing 5 mg/ml H37RA
(Mycobacterium tuberculosis, Difco Laboratories, Detroit, Michi-
gan, USA). Additionally, 200 ng pertussis toxin (Sigma Aldrich) was
injected i.p. on days 0 and 2 post-CFA injection [18]. EAE disease
severity was scored according to the previously described 0e4 scale
[31] as follows: 0, no clinical signs; 0.5, tail weakness; 1, completely
limp tail; 1.5, limp tail and hindlimb weakness; 2, unilateral hin-
dlimb paralysis; 2.5, bilateral partial hindlimb paralysis; 3, bilateral
hindlimb paralysis; 3.5, complete hindlimb and unilateral forelimb
paralysis; and 4, death or moribund.2.3. Adoptive EAE
Adoptive EAE was performed according to Miller [32] and Axtell
[33]. Brieﬂy, 8e10 days after immunization, the splenic and
draining lymph node cells from MOG35e55 peptide-immunized
Nr2f6þ/þ or Nr2f6/ mice were isolated and depleted of red
blood cells with lysis buffer (R&D Systems). The cells were re-
stimulated with 25 mg/ml MOG35e55 (3  106/ml in IMDM) in the
presence of 25 ng IL-23. After 5 days in culture, the cells were
harvested, and 2  107 cells were transferred into healthy Nr2f6þ/þ
recipients via i.p. injection. Pertussis toxin (200 ng/mouse; Sigma)
was administered i.p. on the day of the adoptive transfer as well as
48 h after transfer. Signs of EAE disease were scored using a 0e4
scale, according to the methods of Hirota [13]. The frequencies of
donor CD4þ T cells producing IL-17 and IFNgwere assessed by FACS
prior to transfer.2.4. Preparation of mononuclear inﬁltrating cells
Mononuclear inﬁltrating cells were isolated from the CNS and
SC as described by Korn and Hermann-Kleiter [18,34]. Brieﬂy, the
mice were perfused through the left cardiac ventricle, and the brain
and SC were removed and ﬂushed with PBS. The tissues were then
digested with collagenase D (2.5 mg/ml; Roche Diagnostics) and
DNaseI (1 mg/ml; Sigma) at 37 C for 45 min. The homogenate was
passed through a 70-mm cell strainer, and the mononuclear cells
were isolated by Percoll density centrifugation (70%e30%). The
cells were removed from the interphase, washed, and resuspended
in IMDM complete medium (10% FCS, 2 mM L-Glutamine and 50
U ml1 penicillin/streptomycin).2.5. In vitro Th differentiation
Naive CD4þ T cells were isolated using the CD4þ CD62Lþ T cell
isolation kit II (Miltenyi Biotech). Polarization of these CD4þ T cells
into Th17 cells was performed in complete IMDM medium sup-
plemented with TGFb (5 ng/ml), IL-6 (20 ng/ml), IL-23 (10 ng/ml),
anti-IFNg, and anti-IL-4 (2 mg/ml). The polarization of CD4þ T cells
into iTregs was performed in complete IMDM medium supple-
mented with TGFb (5 ng/ml) plus hIL-2 (25 ng/ml).2.6. Gel mobility-shift assay
Naive resting and Th1- and Th17-differentiated CD4þ T cells
were lysed, and nuclear extracts were prepared [18]. The following
oligonucleotides were used, and the core binding motifs are
underlined:
min. hIl17a (NFAT o3) [35] 50-CATTGGGGGCGGAAATTTTAAC
CAA-30;
min. Il17a (NFAT o3) mouse 50-CATTTGAGGATGGAATCTTTACT
CAAA-30 and mutated.
Il17a (NFAT mo3) 50-CATTAAGGGATGGAATCTTTACTCAAA-30.
NFAT Il17a CNS2 50-TTGGTTGGAAAAAAAAATGGAAAGTTTTCT
GACCCACTTT-30
RORE Il17a CNS2 [16] 50-GAAAGTTTTCTGACCCACTTTAAAT
CAATTT-30.
NR2F6-speciﬁc EMSAs were performed using the probe set for
the COUP-TF family member NR2F1 (Panomics). This probe
contains the same core binding sequence as NR2F6, as underlined
(50-GTGTCAAAGGTCGTGTCAAAGGTC-30). Antibodies targeting
NR2F6 (R&D PP-N2025-00), NFATc1 (ABR ma3-024), and RORg(t)
(eBioscience 14-6981) were used for the supershift experiments.
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Table 1
Transfer of MOG35e55-speciﬁc Th17 cells into wild-type recipients.
Genotype Incident Onset day (mean  s.e.m) Max. score (mean  s.e.m)
Control 0% (0/1) NA NA
Nr2f6þ/þ 100% (4/4) d15  0.2 1.38  0.38
Nr2f6/ 100% (4/4) d13  0.25 2.75  0.25
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The chromatin immunoprecipitation (ChIP) assay was per-
formed with a ChIP assay kit according to the recommendations of
the manufacturer (Imgenex) in combination with the Cold Spring
Harbor protocol [36]. Brieﬂy, Nr2f6þ/þ and Nr2f6-deﬁcient naïve T
cells were isolated using the CD4þ CD62Lþ T cell isolation kit II
(Miltenyi Biotech). The polarization of CD4þ T cells into Th17 cells
was performed using solid-phase anti-CD3 (5 mg/ml) and soluble
anti-CD28 (1 mg/ml) in complete IMDM medium supplemented
with TGFb (5 ng/ml), IL-6 (20 ng/ml), IL-23 (10 ng/ml), anti-IFNg,
and anti-IL-4 (2 mg/ml). The cells were harvested and washed once
in IMDM on day 3 and re-stimulated overnight by solid-phase anti-
CD3 (5 mg/ml) in IMDM medium. The Th17 cells were ﬁxed in 1%
formaldehyde at 37 C for 10 min, and the cross-linking was
quenched by the addition of 1.375 M glycine. The cells were then
washed twicewith ice-cold PBS and lysed in cold cell lysis buffer for
ChIP (5 mM PIPES (pH 8.0), 85 mM KCl, 0.5% Nonidet P-40 (NP-40))
for 10 min. The cell pellets were lysed following centrifugation in
1 ml nuclei lysis buffer for ChIP (50 mM Tris-Cl (pH 8.0), 10 mM
EDTA, 1% SDS) supplemented with protease inhibitors and were
incubated for 10 min on ice. Following sonication with 25e30 s
pulses using a Bioruptor Next Generation (Diagenode), the
samples were centrifuged for 10 min at 12.000 rpm. The sheared
chromatin was used to setup immunoprecipitation reactions with
5 mg of the indicated Abs (IgG sc-2027 Santa Cruz; NFATc1 sc-7294,
RORyt sc-28559; H3K4 ab8580 Abcam, NR2F6 R&D PP-N2025-00)
at 4 C overnight. Magna ChIP protein G magnetic beads were
added for 2 h, and the samples were sequentially washed oncewith
the buffers provided by the supplier (IMGENEX; high to low salt).
The DNA-protein complex was eluted by heating at 65 C overnight,
and the DNA was eluted using the IPure kit (Diagenode). Real-time
PCRwas performedwith the following primers and probes using an
ABI PRIM 7000 Sequence Detection System (Applied Biosystems):
Il17a minimal promoter (243 to 176) 50-
GAACTTCTGCCCTTCCCATCT-30 and 50-CAGCACAGAACCACCCCTTT-
30 with the probe.
50-FAM-CCTTCGAGACAGATGTTGCCCGTCA-TAMRA-30 [8]; and
Il17a CNS2 50-CCGTTTAGACTTGAAACCCAGTC-30 and 50-GTACC-
TATGTGTTAGGAGGCGC-30, with the probe 50-FAM-CAAGTGGGGGC-
CATCAGTC-TAMRA-30 [16].
2.8. Flow cytometry
Cells were either unstimulated or stimulated with PMA/ion-
omycin (50ng/ml; 500 ng/ml) for 5 h in the presence of Golgi stop (BD
Bioscience). The expression of CD4, IL-17, IL-17A, IFNg (BD Pharmin-
gen), RORgt, and Foxp3 (eBioscience) was analyzed by intracellular
staining (Cytoﬁx/Cytoperm kit plus, BD Biosciences or eBioscience
buffer) followed by FACS analysis (FACSCalibur, BD Biosciences).
2.9. Gene expression analysis
TotalRNAwas isolatedusing theQiagenRNeasykit. Theﬁrst-strand
cDNA synthesis was performed using oligo(dT) primers (Promega)
with theQiagenOmniscript RT kit, according to the instructions of theFig. 1. Immune cell-intrinsic NR2F6 is required to suppress EAE disease progression. (A)
immunized Nr2f6þ/þ or Nr2f6/ mice were restimulated in vitro with MOG35e55 in the pre
staining of IL-17A (CD4þ gated events). (B) Quantiﬁcation of the positively gated IL-17A CD4þ
mice per group. (C) EAE disease time course of naïve syngeneic Nr2f6þ/þmice injected intrap
stimulated cells. (D) CD4þ Foxp3þ staining revealed no signiﬁcant difference in CNS-inﬁltrati
FACS dot blot of Foxp3þ cells gated on CD4þ T cells. Data are representative of two independe
cytometry of mononuclear cells isolated from the brains of mice with adoptively transferr
sentative example from the adoptive transfer of Nr2f6þ/þ or Nr2f6/ cells or PBS into Nr2f6
cells inﬁltrating the CNS is shown. Data are representative of two independent experimentsupplier. The expression analysis was performed using real-time PCR
with an ABI PRIM 7000 Sequence Detection System (Applied Bio-
systems) with TaqMan gene expression assays, and all expression
patterns were normalized to that of Gapdh. The expression levels of
wildtype Th17-stimulated cells were arbitrarily set to 100.
2.10. Western blotting
Cells were stimulated for the indicated lengths of time, washed,
and lysed in lysis buffer. Whole-cell extracts or nuclear extracts
were electrophoresed on NuPAGE gels (Invitrogen) and transferred
to PVDF membranes. Protein lysates were subjected to immuno-
blotting with antibodies against Rory (Santa Cruz sc-28559), ROR
gamma (t) (eBioscience 14-6981), NFATc1 (Santa Cruz sc-7294),
NFATc2 (Santa Cruz sc-7295x), HA (Covance MMs-101P) and DNA
polymerase-d (Santa Cruz sc-10784).
2.11. Co-immunoprecipitation
The co-immunoprecipitation analysis was described previ-
ously [37].
2.12. Statistical analysis
Differences between genotypes were analyzed using the
unpaired Student’s t test. Signiﬁcant differences are indicated as
follows: *p < 0.05; **p < 0.01; or ***p < 0.001.
3. Results
3.1. Immune cell-intrinsic NR2F6 is required to suppress EAE disease
progression
Nr2f6-deﬁcient mice are more susceptible to the induction of
experimental autoimmune encephalomyelitis (EAE) [18]. To
exclude the possibility that the enhanced Th17 development and
EAE disease progression in Nr2f6-deﬁcient mice is caused by
altered dendritic or microglial cells, we employed an adoptive EAE
lymphocyte transfer model. Splenocytes and draining lymph node
cells from MOG35e55-immunized Nr2f6þ/þ or Nr2f6/ mice were
stimulated ex vivo with MOG35e55 in the presence of IL-23 for 5
days and were then injected into naïve Nr2f6þ/þ recipient mice. The
percentage of differentiating CD4þ IL-17þ-producing cells was
determined by FACS analysis prior to transfer into the recipient
animals. Despite comparable total CD4þ IL-17þ cell numbers, the
Nr2f6/ CD4þ T cells demonstrated signiﬁcantly increased IL-17
expression on a per-cell basis (Fig. 1 A and B).For adoptive EAE, the draining lymph node cells and splenocytes from MOG35e55-
sence of IL-23 for 5 days and were then analyzed by ﬂow cytometry for intracellular
cells is presented. Data are representative of two independent experiments with three
eritoneally with either (2  107) Nr2f6þ/þ or Nr2f6/ in vivo EAE-primed and in vitro re-
ng regulatory T cells between the experimental groups, as shown by one representative
nt experiments with three mice per group. Error bars, mean  s.e.m. *p < 0.05. (E) Flow
ed disease. The IL-17A- and IFNg-positive cells were gated on CD4þ cells; one repre-
þ/þ mice is shown. (F) The quantiﬁcation of the CD4-positively gated IL-17A and IFNg
s with three mice per group. Error bars, mean  s.e.m. *p < 0.05; **p < 0.01.
Th0 Th1 Th2 Th17 iTregs
Foxp3
2000
1600
1200
800
400
0
Th0 Th1 Th2 Th17 iTregs
Il17a
2500
2000
1500
1000
500
0
20
Il4
Th0 Th1 Th2 Th17 iTregs
16
12
8
4
0
Ifnγ
120
100
80
60
40
20
0
Th0 Th1 Th2 Th17 iTregs
re
la
tiv
e 
m
R
N
A 
e
xp
re
ss
io
n
14
Nr2f6
12
10
8
6
4
2
0
Th0 Th1 Th2 Th17 iTregs
18
16 *
*
IL
-1
7
[ng
/m
l]
6
5
4
3
2
1
0
0 µm 
ova
*
1400
400
0
200
re
la
tiv
e 
m
R
N
A 
e
xp
re
ss
io
n
1200
1000
800
600
Il17a
M Th17
*
Il17f
M Th17
*
Il21
M Th17
*
M Th17
Il22
M Th17
Rorc
1 µm ova
Th17
Nr2f6
+/+
Nr2f6
–/–
Nr2f6
+/+OTII Nr2f6–/–OTII
A
C
D F
E G
B
DNA polymerase
RORγ t
Nr2f6
+/+
 Nr2f6
–/–
M Th17 M Th17
Nr2f6
+/+
Nr2f6
–/–
R
O
Rγ
t
104
104
103
103
102
102
101
101
100
100
68.5% 17.7%
77.4% 36.5%
104
104
103
103
102
102
101
101
100
100
IL
-1
7
FSC FSC
1023 10230 0
Nr2f6
+/+
Nr2f6
–/–
Fo
xp
3
104
104
103
103
102
102
101
101
100
100
%
 o
f F
ox
p3
 p
os
itiv
e 
ce
lls
60
50
40
30
20
10
0
TGFβ+IL-2
64.9%
64.6%
FSC
10230
Fig. 2. Nr2f6 is mainly expressed in the Th2 and Th17 subset and suppresses Il17a, Il17f and Il21 transcription but not RORgt or iTreg induction. (A) Naïve CD4þ T cells were
differentiated under neutral Th0, Th1, Th2, Th17 and iTreg conditions, and Nr2f6mRNA expression was assessed by qRT-PCR. The Th subset-polarizing conditions were controlled by
mRNA expression of Ifng (Th1), Il4 (Th2), Il17a (Th17) and Foxp3 (iTregs). The data shown are derived from at least three independent experiments demonstrating consistent results.
qRT-data were normalized to Gapdh expression. Error bars denote the mean  s.e.m. *p < 0.05; expression in the Th0 subset was arbitrarily set to 1. (B) IL-17A secretion by OT-II
N. Hermann-Kleiter et al. / Journal of Autoimmunity 39 (2012) 428e440432
IL
-1
7
[ng
/m
l]
12
10
8
6
4
2
0
Th17
re
la
tiv
e 
m
R
N
A 
e
xp
re
ss
io
n
200
150
100
50
0
Nr2f6
+/+
Nr2f6-Tg85
re
la
tiv
e 
m
R
N
A 
e
xp
re
ss
io
n
120
Nr2f6
100
80
60
40
20
0
M Th17
*
Il17f
M Th17
Rorc
M Th17
*
Il17a
M Th17
*
Il21
M Th17
*
*
Il22
M Th17
min Il17a
A C D E
F G
B
Th17
wt Tg85
wt Tg85
M Th17 M Th17
NFATc1 
supershift
DNA 
polymerase
n. ext.
wt Tg85
M Th17 Th17
NFATc1
NFATc1 AB + + + +
min Il17a
(NFAT o3)
H
Fig. 3. Nr2f6 overexpression suppresses Th17 differentiation in vitro. (A) Wildtype (Nr2f6þ/þ) or Nr2f6-Tg85 (Tg85) CD4þ cells were differentiated under Th17 conditions, and Il17a,
(B) Il17f, (C) Il21, (D) Rorc, (E) and Il22 transcript levels from both genotypes were determined by qRT-PCR. The data shown are derived from three independent experiments and are
normalized to the amounts of Gapdh expression. Expression in the Th17 Nr2f6þ/þ differentiated cells subset was arbitrarily set to 100 in order to facilitate comparison between the
different cytokines. Error bars denote the mean  s.e.m. *p < 0.05. The error bars denote mean  s.e.m. *p < 0.05. (F) Expression of Nr2f6 in Nr2f6þ/þ or Nr2f6-Tg85 un-stimulated or
Th17-differentiated CD4þ T cells. Note the approximate 4-fold increase in expression in the Tg85 transgenic NR2F6 cells. (G) Supernatants from wildtype (Nr2f6þ/þ) or Nr2f6-Tg85
(Tg85) CD4þ Th17-differentiated cells were used to measure IL-17 secretion via BioPlex. (H) EMSA analysis of nuclear extracts prepared fromwildtype (Nr2f6þ/þ) or Tg85 CD4þ Th17-
differentiated cells hybridized to the min Il17a (NFAT o3) oligonucleotide and supershifted with an NFATc1 antibody. Equal NFAT nuclear translocationwas observed by western blot,
and DNA polymerase d was used as the loading control. One of three independent experiments is shown.
N. Hermann-Kleiter et al. / Journal of Autoimmunity 39 (2012) 428e440 433Naïve Nr2f6þ/þ mice treated with MOG35e55-primed Nr2f6-
deﬁcient cells developed signiﬁcantly more severe EAE disease
without changing Foxp3 levels of inﬁltrating CD4þ T cells (Fig. 1C
and D and Table 1). Signiﬁcantly higher levels of inﬁltrating CD4þ
IL-17þ T cells were found in the central nervous system of mice that
received MOG35e55-primed Nr2f6/ cells in comparison to recipi-
ents that received MOG35e55-primed Nr2f6þ/þ cells (Fig. 1E and F).
3.2. Attenuation of Il17a, Il17f and Il21 gene transcription in
Nr2f6/ CD4þ Th17 cells
We have previously shown that NR2F6 potently antagonizes the
ability of CD4þ Th17 cells to secrete the signature cytokine IL-17ANr2f6þ/þ or OT-II Nr2f6/ CD4þ Th17 cells in the presence of unstimulated DCs or DCs pulse
shown are derived from three independent experiments. (C) Naïve Nr2f6þ/þ or Nr2f6/ CD4þ
Il17a, Il17f, Il21, Rorc and Il22 mRNA was assessed by qRT-PCR. The data shown are derived fr
were normalized to Gapdh expression. Expression in the Th17 Nr2f6þ/þ differentiated cells s
cytokines. Error bars denote the mean  s.e.m. *p < 0.05. (D) Western blot analysis of nu
differentiated cells revealed no differences in the amount of nuclear RORgt protein; DNA
independent experiments. (E) Flow cytometry of in vitro Th17- (TGFb, IL-6, IL-23, aIL-4, aIFNg
staining could be observed, although IL-17 staining was different between the two genotyp
gated Foxp3þ CD4þ cells stimulated with TGFb in combination with IL-2. Data represent a sum
cytometry of in vitro-differentiated (TGFbþ IL-2) Nr2f6þ/þ or Nr2f6/ Foxp3-positive CD4þfollowing TCR stimulation under Th17-differentiating conditions
[18]. To understand why NR2F6 is critical in CD4þ Th17 T cells, we
analyzed its expression in the different Th subsets. qRT-PCR of
Nr2f6þ/þ-differentiated CD4þ Th0, Th1, Th2, Th17 and iTreg T cell
subsets revealed that Nr2f6 mRNA is predominately expressed in
the Th17 and Th2 subsets but not the Th1 and iTreg subsets.
Speciﬁc Th subset differentiation was controlled by the
expression patterns of key cytokines associated with Th1 (Ifng), Th2
(Il4) and Th17 (Il17a) cells as well as that of the Treg-speciﬁc
transcription factor Foxp3 (Fig. 2A).
We next crossed Nr2f6-deﬁcient mice to an OT-II TCR-transgenic
background to investigate Th17 cell functions during physiological
stimulation with cognate antigen. Nr2f6-deﬁcient OT-II TCR-s with 1 mm Ova for 3 d was measured in the supernatant via BioPlex method. The data
T cells were Th17- (TGFb, IL-6, IL-23, aIL-4, aIFNg) differentiated, and the expression of
om at least three independent experiments demonstrating consistent results. qRT-data
ubset was arbitrarily set to 100 in order to facilitate comparison between the different
clear extracts from Nr2f6þ/þ or Nr2f6/ CD4þ Th17- (TGFb, IL-6, IL-23, aIL-4, aIFNg)
polymerase was used as a loading control. The data shown represent one of three
) differentiated Nr2f6þ/þ or Nr2f6/ CD4þ Th17 cells. No signiﬁcant difference in RORgt
es. One representative example of three is shown. (F) Quantiﬁcation of the positively
mary of three independent experiments. Error bars denote the mean  s.e.m. (G) Flow
T cells; one representative example is shown.
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IL-17A secretion (Fig. 2B) but manifested comparable levels of
RORgt expression (data not shown).
Next, we performed a more detailed expression proﬁle analysis
of Il17a, Il17f, Il21 and Il22, as well as the key transcription factor
Rorc, during Th17 differentiation. When naïve Nr2f6þ/þ or Nr2f6-
deﬁcient CD4þ T cells were activated under Th17 differentiation
conditions (TGFb, IL-6, IL-23, aIL-4, aIFNg), the expression levels of
Il17a and Il17f, as well as Il21, were signiﬁcantly higher in the Nr2f6-
deﬁcient CD4þ Th17 cells. The Rorc and Il22 expression levels were
not signiﬁcantly altered (Fig. 2C), indicating that NR2F6-mediated
regulation of the Il17a, Il17f and Il21 promoters is context-
dependent. RORgt protein levels were also analyzed by western
blot and intracellular FACS analysis, and again no signiﬁcant
differences were observed in Nr2f6-deﬁcient CD4þ Th17 cells
despite a slight increase in the intracellular FACS analysis (Fig. 2D
and E).
Exposure of naïve CD4þ T cells to TGFb in the presence of IL-6
triggers Th17 differentiation, whereas the presence of IL-2 favors
differentiation into Foxp3-expressing iTregs. We therefore investi-
gated the potential for naïve Nr2f6-deﬁcient CD4þ T cells to
differentiate into Foxp3-expressing iTregs. The differentiation of
Nr2f6þ/þ or Nr2f6-deﬁcient naïve CD4þ T cells with TGFb plus IL-2
resulted in equivalent numbers of Foxp3þ CD4þ T cells, which
suggests that NR2F6 does not play an essential role in the differ-
entiation of iTregs (Fig. 2F and G). In support of this ﬁnding, the
Nr2f6-deﬁcient Treg suppressive functions were not signiﬁcantly
altered (data not shown).proteins with either a defective DNA binding domain (C112S; S89E) or ligand-binding doma
the DNA (NR2F6-C112S) and ligand-binding domain mutants (NR2F6 E383Stop; LL/AA) bou
positive control. The binding of NR2F6 is dependent on the presence of a supershift NR2F6
Il17a promoter region containing the min Il17a (NFAT o3) (underlined) (NFAT core sequence
core motif of the second half site of the NR2F6 binding sites (highlighted in red), are shown.
mo3): 50-CCTC ATTAAGGGAT GGAATCTTTA CTCAAA -30 . (H) EMSA analysis revealed that bin
this TGA represents a NR2F6 in vivo binding half site. NR2F6 can also bind to the RORE site3.3. Forced overexpression of NR2F6 suppresses Th17 cell function
To further validate the negative regulatory function of NR2F6,
we generated a transgenic mouse line overexpressing NR2F6.
Nr2f6-Tg85 mice exhibited severely suppressed CD4þ Th17 cell
functions, as measured by IL-17A secretion and Il17a, Il17f and Il21
expression levels (Fig. 3AeC). Similar to the Nr2f6/ cells, Rorc and
Il22 were not signiﬁcantly different from wildtype levels
(Fig. 3DeE). The qRT-PCR results revealed an approximate four-fold
increase in Nr2f6 expression in Nr2f6-Tg85 CD4þ cells during Th17
differentiation as compared to wildtype cells (Fig. 3F and G).
We have previously shown that NFAT binding to a speciﬁc
minimal Il17a promoter oligonucleotide (hereafter referred to as
“min Il17a NFAT o3”) is enhanced in Nr2f6-deﬁcient in vitro-differ-
entiated CD4þ Th17 cells [18]. Therefore, we analyzed NFAT binding
behavior using the nuclear extracts of Tg85-NR2F6 CD4þ Th17-
differentiated cells and found reduced NFAT binding in cells of
the transgenic line, although the nuclear translocation of NFAT was
not altered (Fig. 3H).3.4. NR2F6 binds directly to the minimal Il17a promoter
To understand the mode of Il17a repression by NR2F6 in further
detail, we determinedwhether recombinant NR2F6-GSTcould bind
to the Il17a promoter sequence in vitro. Despite the lack of
a consensus idealized hormone response element (HRE) half site
containing a TGACCG motif, NR2F6-GST binding to the minimalin (LL/AA; E383Stop). (E) In vitro-derived NR2F6 (from Origen) and NR2F6-GST but not
nd to the min Il17a (NFAT o3) in EMSAs (F) a COUP-TF oligonucleotide was used as the
antibody. One of three independent experiments is shown. (G) Sequence of the mouse
is highlighted in green), as well as the two HREs (conﬁrmed for RORgt [46];) and the
min Il17a (NFAT o3): 50-CCTC ATTTGAGGAT GGAATCTTTA CTCAAA -30; min Il17a (NFAT
ding of NR2F6 was only disturbed when using min. Il17a (NFAT mo3), suggesting that
s [46] within the min. Il17a promoter. One of two independent experiments is shown.
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electromobility shift assays (EMSA) in vitro (Fig. 4A).
Next, we performed chromatin immunoprecipitation (ChIP)
assays with recombinant Strep-epitope-tagged NR2F6 and NFAT
from transiently transfected Jurkat cells. Whereas recombinant
NR2F6 bound to the minimal Il17a promoter under resting condi-
tions, recombinant NFAT did not. When the Jurkat cells were
stimulated with PMA/Iono, recombinant NR2F6 binding dimin-
ished, whereas recombinant NFAT binding was induced (Fig. 4B). In
primary CD4þ cells, we detected NR2F6 binding within theminimal
Il17a promoter region in resting and in vitro-generated Th0 cells,
whereas this binding was lost in Th17 differentiated cells. More-
over, no relevant binding could be observed in the Nr2f6-deﬁcient
cells used as negative controls for conﬁrming the speciﬁcity of the
NR2F6-ChIP antibody (Fig. 4C).
Using different mutant recombinant proteins for the DNA
binding domain (DBD) and the ligand-binding domain (LBD), we
determined the NR2F6 domains that are important for DNA binding
(Fig. 4D). In vitro, proper binding to the minimal Il17a NFAT o3
promoter oligonucleotide was dependent on both the LBD and DBD
of NR2F6 and occurred only in the presence of the NR2F6 antibody,
indicating dependency on a homodimerization partner (Fig. 4E).
When a chicken ovalbumin upstream promoter transcription factor
(COUP-TF)-speciﬁc oligonucleotide sequence containing two HRE
half sites was used as a positive control, NR2F6-GST binding again
was dependent on the presence of both an intact DBD and LBD
(Fig. 4F). To deﬁne the direct binding sequence of NR2F6, we per-
formed mutational analysis and used competitor DNA oligonucle-
otide sequences. These experiments revealed the presence of
a bona-ﬁde half site within the minimal Il17a promoter directly 4
base pairs upstream of the NFAT core binding sequence of the
minimal Il17a NFAT o3 promoter oligonucleotide (Fig. 4G and H).
3.5. NR2F6 directly interacts with NFAT in a DNA scaffold-
dependent way
To understand how NR2F6 inhibits NFAT binding to the Il17a
promoter, we co-expressed NR2F6 with HA-Strep-epitope-tagged
NFATc1 or NFATc2 together with a plasmid encoding the Il17a
promoter (1.3 kb) in Jurkat cells. Pull-down assays revealed that
NR2F6 could physically interact with both NFATc1 and NFATc2 in
resting Jurkat cells, and this association was dependent on the
presence of DNA, as ethidium bromide disrupted this physical
interaction (Fig. 5A). Of note, NR2F6 did not bind to RORgt in the
same experimental setup (data not shown). Additionally, NR2F6
could only physically interact with NFATc1/c2 if the DBD and LBD
domains were intact, as demonstrated using DNA (C112S; S89E)
and ligand binding (LL/AA: E383Stop) domain-mutant recombinant
proteins, conﬁrming the DNA-dependent association of this protein
complex (Fig. 5B). This ﬁnding suggests that NFATc1 and NFATc2 are
the direct physical targets of DNA-bound NR2F6 in resting T cells.
3.6. NR2F6 suppresses NFAT and RORgt binding to the CNS2 Il17a
promoter region
The Il17a CNS2 region contains HREs that have been shown to
bind RORa and RORgt, which both strongly enhance the tran-
scription of Il17a [16]. The HREs of the nuclear receptor family are
highly homologous; therefore, we hypothesized that NR2F6may be
capable of binding this region as well. The capacity of recombinantIl17a RORg oligonucleotide. The speciﬁc binding of RORgt was conﬁrmed using a RORgt sup
(c.m. oligo). Unspeciﬁc binding of the RORc oligonucleotide was validated via comparison w
blots for nuclear extracts probed with DNA polymerase d. The data shown are derived fromNR2F6 to bind to this sequencewas tested via EMSA. In fact, NR2F6-
GST was able to directly bind to the oligonucleotide containing the
HRE within CNS2, hereafter referred to as “CNS2 Il17a RORgt”,
in vitro (Fig. 6A) (previously published by Yang [16]). The speciﬁcity
of this oligonucleotide was further veriﬁed using Rorc-deﬁcient
CD4þ Th17 cells as a negative control (Fig. 6B).
We next analyzed the capacity of NFAT to bind to the CNS2
region in Nr2f6-deﬁcient CD4þ Th17 nuclear extracts and found
that binding was enhanced in nuclear extracts derived from
Nr2f6-deﬁcient cells, compared to wildtype cells, using a CNS2
Il17a NFAT oligonucleotide (Fig. 6C). The NFAT binding capacity at
the CNS2 locus was also analyzed in Nr2f6-Tg85 Th17 nuclear
extracts, and reduced binding was consistently observed in Nr2f6-
Tg85 CD4þ Th17-differentiated nuclear extracts (Fig. 6D). The
NFAT binding capacity for a speciﬁc Itk-dependent NFAT site
at 3085 bp of the Il17a-proximal region [9] which is not ﬂanked
by an HRE, was not altered in Nr2f6-deﬁcient Th17 cells (data not
shown).
Thus, we hypothesized that RORgt binding may be altered in
Nr2f6-deﬁcient CD4þ Th17 cells because both of these nuclear
receptors can bind to the sameHREs. In fact, an EMSA analysis using
the CNS2 Il17a RORgt oligonucleotide probe revealed enhanced
RORgt binding inNr2f6-deﬁcient CD4þ Th17 nuclear extracts but no
binding in Th1-derived nuclear extracts (Fig. 6E). Reduced RORgt
binding was observed in nuclear extracts from Nr2f6-Tg85 CD4þ
Th17-differentiated cells (Fig. 6F).
3.7. Loss of Nr2f6 enhances NFAT and RORgt binding capabilities at
the CNS2 and minimal Il17a promoter regions
To validate the EMSA results through an independent
approach, we also performed ChIP analysis using NFAT, RORgt,
H3K4 and IgG antibodies and two different primer pairs spanning
the minimal and CNS2 regions of the Il17a promoter [7,8]. Wild-
type and Nr2f6-deﬁcient naïve CD4þ cells were differentiated into
Th0 and Th17 subsets for 3 days and subsequently re-stimulated
overnight with aCD3. Signiﬁcantly enhanced binding of NFATc1
and RORgt to both the CNS2 and minimal Il17a promoter regions
was detected in Nr2f6-deﬁcient CD4þ Th17 cells. These data
strongly suggest that NR2F6 inhibits the promoter activity of Il17a
not only by suppressing NFAT but also by antagonizing RORgt
binding (Fig. 7). The proposed regulation of Il17a transcription by
NR2F6 is summarized in Fig. 8.
4. Discussion
How Th17 cell-mediated Il17a promoter activation is initiated
and maintained is an area of active research. Here, we demon-
strated that the nuclear orphan receptor NR2F6 can directly bind to
the Il17a locus and interferewith the DNA-binding capacity of NFAT
at the Il17a minimal promoter and CNS2 region. NFAT has been
shown to play a critical role in the activation of the Il17a locus, as
well as in EAE disease progression, through its binding to the Il17a
promoter, and these ﬁndings have also been conﬁrmed for the
minimal promoter and several CNS regions [6,9,35,38].
In Nr2f6-deﬁcient Th17 CD4þ T cells, NFAT binding to the Il17a-
Il17f locus was not increased overall but was speciﬁcally enhanced
at sites ﬂanked by an HRE, indicating that the trans-repression of
NFAT by NR2F6 is dependent on the close proximity of these two
sites.ershift antibody as well as a cold (c.c. oligo) and mutant competition oligonucleotide
ith Rorc/ CD4þ Th17 cells (B). Equal loading was conﬁrmed by performing western
at least three independent experiments demonstrating consistent results.
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N. Hermann-Kleiter et al. / Journal of Autoimmunity 39 (2012) 428e440438NR2F6 directly interacts with NFAT in a DNA scaffold-dependent
fashion, which is in contrast to the mechanism proposed for the
vitamin D receptor (VDR), whereby the VDR directly competes with
NFATc1 binding to the two binding sites within the humanminimal
Il17a promoter [39].
We propose that the functionally important interaction
between NR2F6 and NFAT occurs upon suboptimal antigen stimu-
lation in CD4þ T cells. Moreover, NR2F6-NFAT sequestration may be
the mechanism by which NR2F6 blocks NFAT-mediated Il17a
transactivation to prevent exaggerated Il17a expression and the
subsequent inﬂammatory response. Along this line of reasoning,
Santalasci et al. [40] have shown recently that NFATc1, as well JUN
and FOS, mRNA levels are signiﬁcantly lower in human Th17 cells
than in the Th1 subset.
Il21 expression, which is also highly dependent on the activation
of the transcription factor NFAT [41e43] is also exaggerated in
Nr2f6-deﬁcient Th17 CD4þ T cells, although the detailed molecular
mechanism responsible remains to be elucidated. In fact, most of
the molecular mechanisms responsible for the effects of nuclear
receptor ligands and/or cell-speciﬁc nuclear receptor deletion have
not been determined [27]; in particular, it is unclear how speciﬁcity
is achieved despite highly homologous hormone response (HRE)
DNA-binding core consensus sequences. PPARg suppresses Th17
differentiation by directly interfering with the silencingmediator of
retinoid acid and thyroid hormone receptor (SMRT) clearance from
the Rorc promoter. Therefore, PPARg activation suppresses not only
the expression of Rorc but also that of Il17a, Il17f, Tnfa, Il22, Il21,
Il23r, CCR6 and CCL20 [18]. LXRa (NR1H3) and LXRb (NR1H2)
negatively regulate Th17 differentiation through the activation of
sterol regulatory element binding protein 1 (Srebp-1), which
subsequently binds to the Il17a promoter and directly interferes
with Ahr transactivation [17,44]. LXR reduces the expression of
Rorgt, Il17a, Il17f, Il22, Il23r and Ahr but does not affect that of Il21
and Rora. RAR suppresses Th17 differentiation through retinoic
acid-mediated inhibition of Il23r, Il6r and Irf4 expression and
Smad2/3 phosphorylation via the TGFb receptor pathway [45]. The
vitamin D receptor (VDR), either alone or in combinationwith RXR,
directly competes with NFATc1 binding to the two binding sites
within the human minimal Il17a promoter, recruits histone
deacetylases and sequesters Runx1 from its binding sites under
activating conditions [39]. RORg and RORa are the linage-speciﬁc
transcriptional activators of the Th17 subset; these factors bind as
monomers and potently upregulate Il17 transcription [41]. RORE
consensus binding sequences have been identiﬁed by independent
groups at the minimal Il17a promoter region as well as the CNS2
region 5 kb upstream of the transcription start [5,7,19,41,46]. Wang
et al. [5] have recently reported that the binding of RORgt (and
RORa) to the CNS2 region is necessary to initiate chromatin
remodeling and the subsequent transcriptional activation of the
Il17aeIl17f locus in CD4þ Th17 cells. Foxp3 inhibits RORgt trans-
activation through a DNA-independent, direct physical interaction
[47]. However, both the RORgt and Foxp3 transcription factors are
regulated by Runx1, which also binds within the minimal Il17a
promoter region and binds directly to RORgt, thereby enhancing
Il17a transcription [7].
We have shown that NR2F6 directly binds to these RORE sites
within the Il17a locus and subsequently interferes with the trans-
activation of the Il17a promoter. In Nr2f6-deﬁcient Th17 CD4þ T
cells, RORgt binding was strongly enhanced, particularly at theor anti-IgG. Bound DNA was ampliﬁed by quantitative PCR using primers from either
the minimal Il17a promoter locus (0.2 kb, and 0.9 kb [8]) or the CNS2 Il17a promoter
locus (5 kb) [16], and the results are presented relative to the input DNA. The IgG
background levels are shown. Data are pooled from three independent experiments.
The error bars denote the mean  s.e.m. *p < 0.05.
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RORgt DNA binding. To our knowledge, these data represent the
ﬁrst example of two nuclear orphan receptors with opposing
functions binding to the same HRE elements within the Il17a locus.
The concept that related transcription factors can bind the same
elements within the Il17a locus has already been demonstrated for
STAT3 and STAT5 [48]. However, in contrast to the opposing roles of
the STAT family members, which are activated by the cytokine
receptors IL-2R and IL-6R, respectively, NR2F6 binds to the HRE in
resting cells.
Despite emerging evidence for the key role of nuclear receptor
signaling in the regulation of Th17 cell differentiation and function,
the molecular mechanisms responsible have remained elusive. The
results presented here suggest that in contrast to the nuclear
receptors that inhibit Th17 differentiation in a receptor activation-
dependent way, such as PPARg, VDR, RAR, ER and LXR, NR2F6 is
prebound to the Il17a locus. Only after stimulation-dependent
displacement of NR2F6 from the Il17a locus can the transcription
factors RORgt and NFAT bind to their Il17a promoter consensus
sequences and subsequently initiate Il17a transcription.5. Conclusion
Our work unravels the molecular mechanisms underlying how
NR2F6 attenuates the DNA accessibility of NFAT and RORgt,
ensuring the proper level of Il17a promoter activation and identiﬁes
NR2F6 as a gatekeeper for the transcriptional suppression of Il17a in
Th17 cells. In contrast to RORgt, which is activated by the cytokines
TGFb and IL-6 in combinationwith the TCR, NR2F6 already binds to
the HRE at the Il17a locus in resting cells as a barrier against
autoimmunity. Given the reported key role of the IL-17 in auto-
immune diseases, our report closes an important gap in theunderstanding of how the expression of this cytokine is controlled
via NR2F6. These ﬁndings support the idea that selective activation
of NR2F6 could represent an innovative therapeutic regimen for
attenuating IL-17A production as a treatment for certain Th17-
mediated autoimmune disorders.Acknowledgment
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